Screener
Vera Therapeutics VERA Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from financing activities | ||
| Proceeds from exercise of stock options and employee stock purchase plan | 3,942 | 1,533 |
| Net cash provided by financing activities | 3,942 | 1,533 |
| Net decrease in cash and cash equivalents | (240,374) | (37,556) |
| Cash and cash equivalents, beginning of period | 354,725 | 92,646 |
| Cash and cash equivalents, end of period | $114,351 | $55,090 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest expense | $1,632 | $1,581 |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's net change in cash?
- Vera Therapeutics (VERA) reported net change in cash of -$240.37M in Q1 2026.
- How has Vera Therapeutics's net change in cash changed year-over-year?
- Vera Therapeutics's net change in cash decreased by 540.0% year-over-year, from -$37.56M to -$240.37M.
- What is the long-term trend for Vera Therapeutics's net change in cash?
- Over 2 years (2023 to 2025), Vera Therapeutics's net change in cash has grown at a 1065.6% compound annual growth rate (CAGR), from $1.93M to $262.08M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Vera Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude